# KEYNOTE-024 (NCT02142738)

> Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: first-line PD-L1-high metastatic non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02142738
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-Small Cell Lung Carcinoma
- Interventions: Pembrolizumab; Paclitaxel; Carboplatin; Pemetrexed; Cisplatin; Gemcitabine
- Enrollment: 305
- Primary outcome: Progression Free Survival (PFS) Rate at Month 6

## Indexed commentary on KEYNOTE-024 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 29
- YouTube: 22
- Podcasts: 19

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-024-nct02142738

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02142738", "email": "<work email>"}; the inbox owner confirms by the emailed link.